Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Phosphate therapy's hidden toll on aging bodies revealed

NCT ID NCT03771105

First seen May 29, 2026 · Last updated Jun 12, 2026 · Updated 5 times

Summary

This study looks at how long-term phosphate therapy affects the kidneys, blood vessels, and heart in people with two rare bone disorders: X-linked hypophosphatemia (XLH) and hereditary hypophosphatemic rickets with hypercalciuria (HHRH). Researchers will measure hormone levels and check organ function in 30 participants aged 13 and older. The goal is to understand the risks of current treatments and how they might influence healthy aging.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPOPHOSPHATEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Yale University School of Medicine

    RECRUITING

    New Haven, Connecticut, 06511, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

hereditary hypophosphatemic rickets with hypercalciuria Hypercalciuria hypophosphatemia idiopathic hypercalciuria rickets X-linked dominant hypophosphatemic rickets

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.